TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03031418

Intervention type: DIAGNOSTIC_TEST
Intervention: ExoDx Prostate Intelliscore
Description: ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
Study: NCT02376816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAVrh74.MCK.micro-Dystrophin
Description: Recombinant adeno-associated virus carrying a truncated micro dystrophin transgene under control of a muscle specific MCK promoter.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAVrh74.MCK.micro-Dystrophin
Description: Recombinant adeno-associated virus carrying a truncated micro dystrophin transgene under control of a muscle specific MCK promoter.
Study: NCT01315327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Description: Omega-3 fatty acids (derived from fish oil)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: Placebo
Study: NCT02593110

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Treadmill Exercise Therapy
Description: Participants randomized to the exercise intervention will receive supervised treadmill exercise three times weekly for six months.
Study: NCT00780676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 100 mg tablet by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 100 mg tablet by mouth daily
Study: NCT00624416

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone synthetic cortisone and Isoproterenol together
Description: Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.
Study: NCT00755469

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-conditioning
Description: The post-conditioning protocol consists of performing 4, 30-second PTCA balloon occlusions followed by 30 seconds of reperfusion for a total of 4 minutes. The first balloon inflation occurs immediately after an angioplasty guidewire is placed through the obstruction in the artery and flow is restored. Following this protocol the vessel will be stented as part of usual practice for treatment of acute MI.
Study: NCT02593110

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Treadmill Exercise Therapy
Description: Participants randomized to the exercise intervention will receive supervised treadmill exercise three times weekly for six months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Participants randomized to the telmisartan arm of the study will take 20 mg or 40 mg of telmisartan daily based on the results of their study run-in. Participants will have their dose increased to up to 80 mg as tolerated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Participants randomized to the telmisartan arm of the study will take 20 mg or 40 mg of telmisartan daily based on the results of their study run-in. Participants will have their dose increased to up to 80 mg as tolerated.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No exercise control group
Description: Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No exercise control group
Description: Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT01235481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise DVD
Description: Exercise DVD added to usual care during maintenance phase of pulmonary rehabilitation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care during maintenance phase post pulmonary rehabilitation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Usual care during maintenance phase post pulmonary rehabilitation
Study: NCT00687609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
Study: NCT02654418

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size)
Study: NCT04638842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Intervention Grief COVID-19
Description: The online Intervention Grief COVID-19 aims to provide to the target population a self-applied intervention based on Cognitive Behavioral Therapy, Mindfulness, Behavioral Activation Therapy, and Positive Psychology, aimed at the Psychoeducation regarding the manifestations of normal grief, advice and guidance on how to find emotional relief, with the aim that survivors allow themselves to validate their experience of emotional pain and recognize it as a normal part of their process of adaptation to loss, what does grief deprived of rights consist of, specifically from the contingency of COVID-19, establish self-care measures for people in different areas of their life (physical, emotional, cognitive and spiritual), direct the survivor to relocate the died in his life without his memory causing suffering, in addition to beginning to resume his life project, adjusting according to his needs and goals. The sessions will be delivered in a frequency of one session every three days.
Study: NCT00276627

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: communication lecture
Description: lecture on communication skills with oncology patients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lecture plus CD-ROM
Description: Interactive CD-ROM about responding to patients' negative emotions. The CD-ROM included tailored feedback on the oncologists' own recorded conversations.
Study: NCT04348045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm A - Olaparib
Description: 300 mg orally twice daily, for a total daily dose of 600mg~Study treatment can be dose-reduced to :~First step : 250 mg twice daily , for a total daily dose of 500 mg Second step: 200 mg twice daily taken twice daily, for a total daily dose of 400 mg No further dose reduction is allowed, and study treatment should be discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM B - durvalumab plus selumetinib
Description: Durvalumab administered IV at a flat dose of 1500 mg on day 1 of every 28-day cycle, Selumetinib Starting Dose : 75 mg twice daily~Study treatment can be dose-reduced to :~Dose Level -1 : 75 mg once daily Dose Level -2 : 50 mg twice daily Dose Level -3 : 50 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARM C FOLFIRI
Description: FOLFIRI every two weeks Irinotecan 180 mg/m2 Intravenous (IV) on day 1 Folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2
Study: NCT00901797

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic Bankart repair
Description: Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ABR+ARIC
Description: Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Through additional anterior superior portal a suture is passed inferior and adjacent to the SSP and through the superior portion of the Sub Scapularis tendon while the arm in 30 degree of external rotation. Tightening the suture on top of the capsule underneath the deltoid. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
Study: NCT04220437

Intervention type: OTHER
Intervention: no interventin
Description: Our stusy analysed the images obtained from ISR patients, no extra intervention was given based on this study.
Study: NCT02124772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).
Study: NCT00780676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 100 mg tablet by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: 75 mg by mouth twice daily.
Study: NCT00539955

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Batterer Intervention
Description: Standard state-mandated batterer intervention program (40 hours)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Alcohol Intervention
Description: Brief alcohol intervention combined with state mandated batterer intervention program
Study: NCT04450147

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi/Qigong vs. Walking/Stretching
Description: Both interventions can be thought of as a form of movement and exercise.
Study: NCT00507754

Intervention type: OTHER
Intervention: T-SPOT TB test
Description: Extra blood draw, followed by ten minutes rest and the injection of Tuberculin subcutaneously on forearm.
Study: NCT04322253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY 1067197)
Description: 10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY 1067197)
Description: 10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY 1067197)
Description: 10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
Study: NCT03704454

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50 mg PYC and then placebo
Description: 4 weeks on PYC, then 4 weeks on placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100 mg PYC and then placebo
Description: 4 weeks on PYC, then 4 weeks on placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo and then 50 mg PYC
Description: 4 weeks on placebo, then 4 weeks on PYC

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo and then 100 mg PYC
Description: 4 weeks on placebo, then 4 weeks of PYC
Study: NCT04213365

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive stimulation sessions coupled with Adapted Physical Activity sessions.
Description: 12 weeks of cognitive stimulation sessions coupled with APA (Adapted Physical Activity) sessions.
Study: NCT00869063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium Patch
Description: Topical 1% diclofenac sodium patch, applied once daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Patch
Description: Matching placebo patch, containing identical constituents to the active drug arm except for diclofenac sodium; applied once daily for 7 days
Study: NCT04565535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Novel donor lifestyle optimisation protocol
Description: Diet based on calorie requirement as calculated by indirect calorimetry. Daily exercise.
Study: NCT02946008

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Delivered over 5 treatment sessions for approximately 1.5 weeks total.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Open, laparoscopic, or robotic radical prostatectomy and pelvic lymph node dissection to remove the prostate, seminal vesicles, and pelvic lymph nodes.
Study: NCT02599727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercises
Description: subjects will perform specific isometric exercises for 10-20 minutes, three times a week throughout the enrollment period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No exercise
Description: Subjects will go on with their life without any specific isometric exercise regimen during the enrollment period
Study: NCT02959736

Intervention type: BEHAVIORAL
Intervention: MATADOC and CRS-R
Description: Behavioural assessments for Disorders of Consciousness

Intervention type: BEHAVIORAL
Intervention: MATADOC and CRS-R
Description: Behavioural assessments for Disorders of Consciousness

Intervention type: BEHAVIORAL
Intervention: MATADOC and CRS-R
Description: Behavioural assessments for Disorders of Consciousness
Study: NCT01392079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab 30 mg s.c. 3 × weekly for 28 days (Days 1, 3, 5; 8, 10, 12; etc.)
Study: NCT03958461

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anti-infective treatment of periodontal pockets
Description: Removing calculi from teeths' periodontal pockets
Study: NCT02138552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octenidine dihydrochloride
Description: Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
Study: NCT03683641

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy
Description: Use ESWT on chronic insertional Achilles tendinopathy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control group
Description: Use sham ESWT on chronic insertional Achilles tendinopathy
Study: NCT02823340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional microneedle RF(United, Peninsula Medical, China)
Study: NCT01829711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Bag Protectant for Moxetumomab pasudotox
Study: NCT01228565

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy + Erbitux® + placebo
Description: 3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; Placebo local application, once a day, every day during the radiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy+Erbitux+OTD70DERM
Description: 3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; OTD70DERM local application, once a day, every day during the radiotherapy
Study: NCT02504762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Hybrid Coronary Intervention = MICS CABG + Percutaneous Coronary Intervention. This study is a surgical intervention, which does not involve a drug or device intervention.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Conventional CABG. This study is a surgical intervention, which does not involve a drug or device intervention.
Study: NCT03477084

Intervention type: BIOLOGICAL
Intervention: ESBL-producing enterobacteriaceae carriage
Description: Carriage of ESBL-producing Escherichia coli or Klebsiella pneumoniae
Study: NCT02695784

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Continuation
Description: This arm will continue to receive probiotics beyond 34 weeks corrected gestation until two months after discharge
Study: NCT01941498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wavelight® Refractive Suite
Description: Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LASIK surgery
Description: Surgical procedure for treating refractive error based on corneal reshaping
Study: NCT00658879

Intervention type: DRUG
Intervention: Somavert (Pegvisomant)
Description: Somavert (Pegvisomant) 10, 15 or 20mg powder and solvent for solution for injection.~Dosage, Frequency : According to Japanese LPD.~Duration : According to the protocol of A6291023, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 5 years after the first administration.
Study: NCT01474200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isolated veno-venous ultrafiltration (AQ)
Description: Aquapheresis treatment (isolated veno-venous ultrafiltration) using the Aquadex FlexFlow System during index hospitalization until the patient's signs and symptoms of fluid overload have improved to the satisfaction of the treating physician. Ultrafiltration rates, duration and frequency of treatment are dependent on the amount of patient fluid excess and on the rate of fluid movement from the interstitial spaces into the vascular compartment during Aquapheresis (Plasma Refill Rate, or PRR)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Loop Diuretics (LD)
Description: IV Loop Diuretics treatment using only FDA approved IV loop diuretics indicated for the treatment of patients with fluid overload. This includes furosemide or other IV loop diuretics administered at equivalent doses to furosemide. Patients will receive either a twice daily IV bolus or continuous IV LD infusions according to the high dose protocol of theDiuretic strategies in patients wth acute decompensated heart failure (DOSE) trial.
Study: NCT01049646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin II
Description: Infusion of a subpressor dose of angiotensin II will be give, this will be 0.5microG/min/kg. Thereafter thre ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Infusion of saline. Thereafter three ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
Study: NCT03714919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Preoperative oral dextromethorphan 1 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Preoperative oral acetaminophen 15 mg/kg
Study: NCT02138552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octenidine dihydrochloride
Description: Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octenidine dihydrochloride
Description: Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
Study: NCT03714919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intraoperative intravenous dexmedetomidine 0.5 μg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intraoperative intravenous ketamine 0.5 mg/kg
Study: NCT00100880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: perfusion-weighted magnetic resonance imaging
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies